ASLAN Pharmaceuticals Pte Ltd
10A Bukit Pasoh Road
Singapore
089824
Tel: +65-6222-4235
Fax: +65-6225-2419
Website: http://aslanpharma.com/
146 articles with ASLAN Pharmaceuticals Pte Ltd
-
BioSpace Global Roundup, Oct. 22
10/22/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial
10/22/2020
-- ASLAN has initiated recruitment of patients into third dos e cohort at sites in the US, Australia and Singapore following successful safety review of second cohort -- ASLAN004 found to be well tolerated at 400mg dose , third cohort will test 600mg dose
-
ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions
10/16/2020
Withnanomolar potency against SARS-CoV-2, ASLAN003 is also being assessed for its potential as a novel therapeutic for COVID-19 and other viruses
-
ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study
9/21/2020
ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that clinical sites in the US and Australia are now open and ready to enrol patients into its multiple ascending dose study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis patients.
-
ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
9/10/2020
ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference.
-
BioSpace Global Roundup, Aug. 27
8/27/2020
Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines. -
ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 StudyInterim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020
8/24/2020
ASLAN Pharmaceuticals announced the resumption of patient recruitment into its randomised, double-blind, placebo-controlled multiple ascending dose study of ASLAN004 in moderate to severe atopic dermatitis.
-
ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020
8/7/2020
ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced its presentation at the BTIG Virtual Biotechnology Conference.
-
ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer
8/3/2020
ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that Dr Kenneth Kobayashi has been appointed Chief Medical Officer.
-
ASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange
7/17/2020
ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced further progress towards a primary listing on the Nasdaq Global Market and receipt of a Notice of Delisting from the Taipei Exchange, an expected step in the TPEx delisting process.
-
ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7/13/2020
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the second quarter ended 30 June 2020 and provided an update on its clinical activities. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said : “As COVID-19 restrictions gradually lift in Singapore we expe
-
ASLAN Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/11/2020
ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, reported financial results for the first quarter ended 31 March 2020 and provided an update on its clinical activities.
-
UPDATE - ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19
4/13/2020
ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment
-
ASLAN Intends to Resume Screening as Soon as Government Restrictions are Lifted and is Taking Steps to Open Sites in Australia to Accelerate Recruitment
4/13/2020
ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment
-
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
3/18/2020
ASLAN Pharmaceuticals reported financial results for the quarter and full year ended 31 December 2019 and provided an update on its clinical activities.
-
ASLAN Pharmaceuticals to Present at 9th Annual SVB Leerink Global Healthcare Conference
2/24/2020
ASLAN Pharmaceuticals Limited announced its presentation at the 9th Annual SVB Leerink Global Healthcare Conference.
-
Clinical Catch-Up: December 2-5
12/9/2019
It was, as usual, a pretty busy week in clinical trial news. Here’s a look. -
ASLAN Pharmaceuticals Announces Closing of US$15 Million Public Offering of American Depositary Shares, Including Full Exercise of Underwriter’s Option to Purchase Additional ADSs
12/5/2019
The gross proceeds to ASLAN, before deducting underwriting discounts, commissions and other offering expenses, were approximately US$14.7 million.
-
ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares
12/3/2019
ASLAN Pharmaceuticals Limited announced that it has priced its previously announced underwritten public offering of 5,124,527 American Depositary Shares at a public offering price of $2.50 per ADS.
-
ASLAN announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004, which is aimed at moderate-to-severe atopic dermatitis.